Browse drugs

… lack of efficacy, six patient decision, five pregnancy) and 37 ixekizumab patients (seven toxicity, 17 loss of response, one patient deci…

…n rate and improvement in all disease activity outcomes suggest ixekizumab as a viable option for patients with multiple b/tsDMARD failure…

…from real-world clinical practice (RWE) remains limited.Methods Adalimumab vs Ixekizumab Real-world Effectiveness is a multicentre cohort …

…arthritis was the most frequent diagnosis (30%).Drugs involved: adalimumab (35%), etanercept (25%), certolizumab (8%), belimumab (6%), ixe…

…: p=0,0482; Anti-IL12/23 vs Anti-TNF: p=0,0480; Risankizumab vs Ustekinumab: p=0,0116. No significant differences were found between Risank…

…n for missing data. Pairwise comparisons were performed between IXE and tumour necrosis factor inhibitors (TNFi), secukinumab (SEC)…

…e Lederballe Grøn, Merete Lund Hetland, et al. Effectiveness of ixekizumab in 709 real-world patients with axial spondyloarthritis and pso…